In this piece, we discussed his experience implementing pharmacogenomic testing at scale, the evolution of their collaboration with SOPHiA GENETICS, and their vision for improving patient care through personalized medicine in the Netherlands and beyond.

Dear Robert, thank you for joining us for this user spotlight! Can you introduce Result Laboratorium and its role within the Dutch healthcare landscape?

Result Laboratorium is your trusted partner in 24/7 high-quality, innovative, and affordable diagnostics, seamlessly integrated into the regional healthcare network. We’re committed to improving and preserving health and well-being, today and for the future.

Our focus is on delivering meaningful results for both healthcare providers and patients, with a collaborative mindset and insightful interpretations of our findings. At Result Laboratorium, we’re confident in what we know, and passionate about uncovering what we don’t yet understand.

Why are Pharmacogenomics particularly important for improving patient care in the Netherlands and beyond?

Pharmacogenomics (PGx) plays a vital role in enhancing patient care in the Netherlands by allowing healthcare providers to tailor drug treatments based on individual genetic profiles. This ensures optimal efficacy and minimizes adverse effects. Given the diversity of the patient population and the complexity of drug responses, pharmacogenomics help ensure patients receive the most appropriate medication and dosage, leading to better clinical outcomes, reduced hospitalizations, and more cost-effective care. 

How long have you been working with SOPHiA GENETICS, and how did the collaboration begin?

We have been working with SOPHiA GENETICS for almost a decade. Initially we sought to expand into next generation sequencing for detecting variants associated with myeloproliferative neoplasms. However, within our lab we did not have the in-house bioinformatics expertise to build the necessary analysis pipelines. SOPHiA GENETICS offered us a robust platform for genomic testing, combined with valuable data analysis tools and decision support systems.

What initially stood out about SOPHiA GENETICS’ approach to pharmacogenomics and how has the partnership evolved as your pharmacogenomics activities matured over the years?

What stood out was the SOPHiA GENETICS comprehensive and systematic approach to pharmacogenomics testing using NGS (Next-Generation Sequencing). The inclusive testing covers a wide range of relevant and even rare variants that traditional tests like qPCR or array technologies might miss. About five years ago, we successfully launched the pharmacogenomics testing for our patients, and since then, the partnership has grown as we continue to refine and expand our testing capabilities.

What operational or analytical challenges were addressed through this collaboration?

Through our collaboration with SOPHiA GENETICS, we tackled several operational and analytical challenges, including optimizing assay processes and data management solutions. Their infrastructure streamlined our testing process, reducing turnaround times with solutions like the universal library preparation. Their bioinformatics tools also made it easier to analyze complex genomic data, such as CYP2D6 genotyping.

How has consistency and standardization been ensured as testing volumes increased?

As testing volumes increased, the SOPHiA GENETICS team helped us ensure consistency and standardization by providing a centralized, online platform, SOPHiA DDM™. Additionally, automated data transfers to SOPHiA DDM™ allow for the analysis to continue even during weekends, while maintaining a unified testing protocol and automated data pipelines.

What motivated Result Laboratorium to adopt a centralized PGx model using SOPHiA DDM™ Dispatch and how does this model enable other institutions to offer PGx without building complex infrastructure?

We adopted a centralized PGx model with SOPHiA GENETICS to streamline the offering of pharmacogenomic testing to a broader range of healthcare providers. By centralizing sequencing and data analysis, we’re able to provide high-quality PGx testing to patients from other institutions without them needing to invest in expensive infrastructure or specialized staff.

Centralizing sequencing ensures consistent, high-quality results by performing all tests under standardized conditions. It also allows us to manage large test volumes more efficiently, ensuring we meet growing demand without compromising accuracy or quality control.

How important are data security, compliance, and cloud reliability when scaling PGx services?

Data security, compliance, and cloud reliability are crucial when scaling PGx services. Given the sensitive nature of genomic data, ensuring that patient information is stored securely and complies with GDPR regulations is non-negotiable. The cloud infrastructure provided by SOPHiA GENETICS is highly reliable and scalable, allowing us to manage and process large datasets securely while meeting all regulatory requirements. This level of reliability is vital for maintaining trust with our patients and healthcare partners.

How does this collaboration position Result Laboratorium as a hub for pharmacogenomic testing in the Netherlands and across Europe?

We are proud that Result Laboratorium plays a key role in the molecular PGx testing landscape. This partnership allows us to offer comprehensive and reliable pharmacogenomic testing to a wide network of healthcare providers, making PGx testing more accessible and supporting the broader adoption of personalized medicine across Europe. 

What advice would you give to laboratories considering a collaborative or hub-and-spoke PGx model?

Prioritize strong partnerships with experienced providers like SOPHiA GENETICS. It’s essential to focus on standardization, scalability, and reliable infrastructure. Equally important is investing in staff education and fostering collaboration across laboratories to create a seamless network that delivers high-quality, consistent results.

In one sentence, how would you summarize the value of your long-lasting collaboration with SOPHiA GENETICS?

Our long-standing collaboration with SG has empowered us to deliver high-quality, scalable, and reliable pharmacogenomic testing to a broader patient population while continually advancing our capabilities through innovative solutions and expert support.

How do you see this partnership supporting future innovation in PGx?

This partnership will continue to drive innovation in PGx by helping us develop new genetic test panels, integrate advanced bioinformatics tools (including full integrated reports), and evolve our services in line with emerging research and technologies in pharmacogenomics.

What excites you most about the future of pharmacogenomics delivery in Europe?

What excites me most is the growing recognition of pharmacogenomics as an essential part of personalized medicine. As more healthcare providers adopt PGx testing, we will see significant improvements in patient outcomes, better treatment protocols, and more efficient healthcare systems across Europe. The ability to tailor drug therapies based on genetic insights will transform the way we approach healthcare and disease prevention.

We would like to warmly thank Dr. Robert Akkers for his participation to this user spotlight, as well as the long-stanting partnership and joint effort in driving innovation in pharmacogenomics in the Netherlands and beyond.